Ms. Jung brings more than 20 years of life sciences corporate strategy and business development, commercial, and investment expertise. Prior to joining Structure, Ms. Jung served as Senior Vice President and Head of Business Development at Sangamo Therapeutics, a genomic medicines company, where she led deals with combined value over $6 billion and upfront consideration exceeding $500 million from broad strategic partnerships with Pfizer, Kite/Gilead, Biogen and Novartis. Ms. Jung also led M&A transactions including the acquisition of TxCell, a public French company. Her previous experiences include corporate development and commercial roles at Adamas Pharmaceuticals, focused on neurological diseases; Ascendancy Healthcare, with a mission to bring innovative treatments to China; and Ipsen, where she led marketing for its specialty endocrinology brand and market research for multiple brands including the US launch of Ipsen’s flagship neurology product. Ms. Jung started her career in biotechnology venture capital and fund management at Bay City Capital and Lombard Odier Darier Hentsch. Ms. Jung received her B.A. in biology from the University of California, Berkeley.